Mifepristone: Judge Orders US FDA To Rethink Need For REMS Restrictions

 
• By Sue Sutter
  
Homework
The FDA failed to "show its work" in justifying the 2023 REMS modifications.

More from Legal & IP

More from Generics Bulletin